newsNICE does not recommend tucatinib in new draft guidance26 October 2021 | By Anna Begley (European Pharmaceutical Review)The UK regulator concluded that breast cancer patients taking tucatinib live longer, but it is unclear how long for and whether it is cost effective.
newsUK grants marketing authorisation to “landmark” breast cancer therapy22 February 2021 | By Hannah Balfour (European Pharmaceutical Review)Seagen's Tukysa® (tucatinib) was approved in the UK as part of a combination regimen for the treatment of adults with locally advanced or metastatic HER2-positive breast cancer.
newsEMA recommends 15 medicines for approval following December meeting14 December 2020 | By Victoria Rees (European Pharmaceutical Review)The EMA's human medicines committee has released its results for the December meeting, suggesting which therapies should receive marketing authorisation.